These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26091736)

  • 1. Why We Should Be Willing to Pay for Hepatitis C Treatment.
    Chhatwal J; Chen Q; Kanwal F
    Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1711-3. PubMed ID: 26091736
    [No Abstract]   [Full Text] [Related]  

  • 2.  The socioeconomic impact of hepatitis C infection and liver transplantation in Mexico.
    Méndez-Sánchez N
    Ann Hepatol; 2012; 11(4):550-1. PubMed ID: 22700637
    [No Abstract]   [Full Text] [Related]  

  • 3. It's time to end insurance restrictions on life-saving hepatitis C treatments.
    Clary R
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP185-7. PubMed ID: 27266946
    [No Abstract]   [Full Text] [Related]  

  • 4. Sticker shock and the price of new therapies for hepatitis C: is it worth it?
    Reau NS; Jensen DM
    Hepatology; 2014 Apr; 59(4):1246-9. PubMed ID: 24493069
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatitis C: An Eastern Perspective.
    Dan YY; Lim SG
    Gastroenterol Clin North Am; 2015 Dec; 44(4):793-805. PubMed ID: 26600220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does patient cost sharing for HCV drugs make sense?
    Lakdawalla DN; Linthicum MT; Vanderpuye-Orgle J
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP188-90. PubMed ID: 27266947
    [No Abstract]   [Full Text] [Related]  

  • 7. 'HepConomics': cost-effective, indeed, but how can we pay for it?
    Athanasakis K; Petrakis I; Kyriopoulos J
    J Viral Hepat; 2015 Aug; 22(8):682. PubMed ID: 25727161
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas.
    Lemoine M; Thursz M
    Semin Liver Dis; 2014 Feb; 34(1):89-97. PubMed ID: 24782262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral treatment initiation costs in chronic hepatitis C.
    Siebert U; Wasem J; Rossol S; Sroczynski G; Aidelsburger P; Ravens-Sieberer U; Kurth BM; Manns MP; McHutchison JG; Wong JB
    Gut; 2005 Jan; 54(1):172-3. PubMed ID: 15591531
    [No Abstract]   [Full Text] [Related]  

  • 10. Access to peginterferon plus ribavirin therapy for hepatitis C in Romania between 2002-2009.
    Gheorghe L; Pascu O; Ceausu E; Csiki IE; Iacob S; Caruntu F; Simionov I; Vadan R
    J Gastrointestin Liver Dis; 2010 Jun; 19(2):161-7. PubMed ID: 20593049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economics of chronic hepatitis B and hepatitis C.
    Rajendra A; Wong JB
    J Hepatol; 2007 Oct; 47(4):608-17. PubMed ID: 17697724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
    JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What about us? Recent advances in the treatment of chronic hepatitis C threaten to leave some parts of the world behind.
    Ahmed F
    J Viral Hepat; 2013 May; 20(5):367-8. PubMed ID: 23565620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
    Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
    J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Will hepatitis C be eradicated in France by 2025?].
    Nau JY
    Rev Med Suisse; 2015 Jun; 11(478):1316-7. PubMed ID: 26211093
    [No Abstract]   [Full Text] [Related]  

  • 16. [Epidemiology of hepatitis C and vaccine perspectives].
    Nau JY
    Rev Med Suisse; 2016 Jan; 12(503):234-5. PubMed ID: 26939196
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost of treating hepatitis C in Germany: a retrospective multicenter analysis.
    Stahmeyer JT; Rossol S; Bert F; Antoni C; Demir M; Hinrichsen H; Hüppe D; Teuber G; Wiebner B; Wedemeyer H; Krauth C
    Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1278-85. PubMed ID: 25144493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Access to hepatitis C treatment: a lesson for the future.].
    Craxì L
    Recenti Prog Med; 2018 Jan; 109(1):25-27. PubMed ID: 29451518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening and Treatment Program to Eliminate Hepatitis C in Egypt.
    Waked I; Esmat G; Elsharkawy A; El-Serafy M; Abdel-Razek W; Ghalab R; Elshishiney G; Salah A; Abdel Megid S; Kabil K; El-Sayed MH; Dabbous H; El Shazly Y; Abo Sliman M; Abou Hashem K; Abdel Gawad S; El Nahas N; El Sobky A; El Sonbaty S; El Tabakh H; Emad E; Gemeah H; Hashem A; Hassany M; Hefnawy N; Hemida AN; Khadary A; Labib K; Mahmoud F; Mamoun S; Marei T; Mekky S; Meshref A; Othman A; Ragab O; Ramadan E; Rehan A; Saad T; Saeed R; Sharshar M; Shawky H; Shawky M; Shehata W; Soror H; Taha M; Talha M; Tealaab A; Zein M; Hashish A; Cordie A; Omar Y; Kamal E; Ammar I; AbdAlla M; El Akel W; Doss W; Zaid H
    N Engl J Med; 2020 Mar; 382(12):1166-1174. PubMed ID: 32187475
    [No Abstract]   [Full Text] [Related]  

  • 20. [A French prospective observational study of the treatment of chronic hepatitis C in drug abusers: a commentary].
    Michel L; Roux P; Cohen J; Carrieri MP
    Gastroenterol Clin Biol; 2009 Jan; 33(1 Pt 1):15-6; author reply 16-7. PubMed ID: 19084361
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.